Many cancer drugs remain unproven 5 years after accelerated

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients'

Related Keywords

United States , Houston , Texas , San Diego , California , American , Ezekiel Emanuel , Jennifer Litton , Edward Cliff , Cherie Duvall Jones , Harvard Medical School , Journal Of The American Medical Association , Md Anderson Cancer Center , University Of Pennsylvania , Drug Administration , American Association For Cancer Research , American Medical Association , American Association , Cancer Research , Harvard Medical , Cancer Center ,